Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Osteolysis 1Multiple Myeloma 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

fludarabine 10Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Tacrolimus 5Mycophenolic Acid 5Melphalan 5Thiotepa 4Peripheral Blood Stem Cell Transplantation 4Busulfan 4AP 1903 reagent 4thymoglobulin 3Sirolimus 3Cord Blood Stem Cell Transplantation 3Alemtuzumab 3Stem Cell Transplantation 2Specimen Handling 2Rituximab 2Platelet Transfusion 2Meropenem 2Cyclosporine 2Biopsy 2Antilymphocyte Serum 2visilizumab 1venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × ARQ 197 × Classical hematology × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡